11.7.2015 Draft for Annual Meeting Attendees

Final report available 12.2015
Table of Contents

<table>
<thead>
<tr>
<th>Page</th>
<th>Section</th>
</tr>
</thead>
<tbody>
<tr>
<td>3</td>
<td>Letter from Bruce</td>
</tr>
<tr>
<td>5</td>
<td>Our Impact: A Year in Review</td>
</tr>
<tr>
<td>5</td>
<td>Making an Impact Together: the Latest Project News</td>
</tr>
<tr>
<td>12</td>
<td>The Launch of CureAccelerator™</td>
</tr>
<tr>
<td>13</td>
<td>Looking Beyond the Horizon</td>
</tr>
<tr>
<td>14</td>
<td>Fiscal Year 14-15 Financial Summary</td>
</tr>
<tr>
<td>14</td>
<td>Our Staff and Leadership Team</td>
</tr>
<tr>
<td>16</td>
<td>Boards and Committees</td>
</tr>
<tr>
<td>18</td>
<td>2014-15 Donors</td>
</tr>
<tr>
<td>20</td>
<td>Stay in Touch</td>
</tr>
</tbody>
</table>
Letter from Bruce

Dear Partners and Friends:

This was an extraordinary year for Cures Within Reach, thanks to the support of our funding and research partners, board members, volunteers and staff. In May, during our spectacular BioScience Awards Midwest event, we launched CureAccelerator™, the world’s first online, interactive platform dedicated to repurposing research. This revolutionary tool, supported by a grant from the Robert Wood Johnson Foundation, will help us carry out our mission of improving patient quality and length of life through repurposing research. We have already funded 9 projects since CureAccelerator launched, and we are planning on 20+ funded CureAccelerator projects in 2016.

We are energized and inspired by the support we’ve received from our initial CureAccelerator partners. Repurposing research can expand quickly and globally using this platform, and we encourage you to tell your funding, research and clinical peers about CureAccelerator so that they can join this worldwide initiative that will drive more treatments to more patients more quickly.

Even outside of CureAccelerator, Cures Within Reach continues to be the global center of collaborations that lead to high-impact repurposing projects. This includes connecting researchers and funders the “old fashioned” way, bringing repurposing stakeholders together at repurposing conferences, and identifying alternative financing models and incentives to support generic drug repurposing, such as our Social Impact Bond Initiative in England, soon to be announced.

We continue to evolve new ways repurposing can quickly and affordably bring cures to the 7,000+ unsolved diseases that impact more than 500 million people across the globe. Over the next three years, we will focus on generic drug repurposing as a primary solution for unsolved diseases, harness emerging social finance mechanisms to create new financial incentives, and create powerful relationships with pharmaceutical partners, to both impact patients and to generate sustainable funding for growing our patient-focused mission and programs.
We can achieve these goals - with your support. Donating your time, expertise and financial resources catalyzes our mission. Help us push forward in the years to come and we will impact the world together.

Best,

Dr. Bruce Bloom

President & Chief Science Officer

Our Impact: A Year in Review

<table>
<thead>
<tr>
<th>2014-15</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>July</strong></td>
</tr>
<tr>
<td>CureAccelerator project discovery process and branding work</td>
</tr>
<tr>
<td><strong>September</strong></td>
</tr>
<tr>
<td><strong>November</strong></td>
</tr>
<tr>
<td>Dynamica Expo El Paso, TX Cultural Transformation for Breakthrough Innovation in Healthcare</td>
</tr>
<tr>
<td><strong>January</strong></td>
</tr>
<tr>
<td>CureAccelerator beta launch</td>
</tr>
<tr>
<td><strong>February</strong></td>
</tr>
<tr>
<td>Development of Orphan Drugs London, UK Off-label Pharmaceutical Use and its Implications for Product Approval</td>
</tr>
<tr>
<td>Drug Repositioning for Rare Diseases London, UK Innovative Partnership and Financing Models for Rare Disease Drug Repurposing</td>
</tr>
<tr>
<td><strong>March</strong></td>
</tr>
<tr>
<td>Canadian Organization for Rare Disorders, Toronto, Ontario Accelerating therapy development (Drug Repurposing Platforms), Clinical Trials on Repurposed Treatments for Immediate Incorporation into Clinical Use</td>
</tr>
<tr>
<td><strong>April</strong></td>
</tr>
<tr>
<td>Bio-IT World Conference &amp; Expo ’15, Boston, MA CureAccelerator™: How a New Global Platform Will Help Propel Cures for the World’s Unsolved Diseases</td>
</tr>
<tr>
<td><strong>May</strong></td>
</tr>
<tr>
<td>BioScience Awards Midwest 2015- over 300 attendees and over $80K raised. Honoring Dr. Richard DiMarchi, Dr. S. Vincent Rajkumar and The Robert Wood Johnson Foundation</td>
</tr>
<tr>
<td>4th Annual Drug Repositioning, Repurposing and Rescue Conference comes to Chicago</td>
</tr>
<tr>
<td><strong>June</strong></td>
</tr>
<tr>
<td>CureAccelerator Public Launch</td>
</tr>
<tr>
<td>Longest Day of Golf raises $28K for pediatric brain cancer research</td>
</tr>
<tr>
<td><strong>July</strong></td>
</tr>
<tr>
<td>CWR Staff expansion</td>
</tr>
<tr>
<td>Disrupting the Process to Accelerate Cures through Repurposing Research Disruptive Pharma Conference, Boston, MA</td>
</tr>
</tbody>
</table>
Making An Impact Together: The Latest Project News

**Laser Ablation Approved to Treat Prostate Cancer**

Several years ago, researchers from the University of Chicago wanted to repurpose an MRI-guided laser ablation used to treat epilepsy, as a treatment for prostate cancer. They had the idea, but no clinical data, so they but weren’t able to obtain NIH funding. They approached Cures Within Reach to identify alternative funding options. Through a grant from Cures Within Reach and support from Visualase, the researchers engaged in a phase Ila clinical trial in the United States to determine if the laser was safe and effective for treating prostate cancer.

The treatment works by inserting a tiny laser catheter into the cancerous prostate, heating it up and monitoring the temperature with MRI. The heat kills the cancerous cells but does not damage the surrounding nerves and other critical structures, so it is minimally invasive and eliminates the incontinence, impotence and other side effects of current therapies. Based on the results of the Cures’ pilot clinical trial, the researchers were funded by the NIH for a larger phase II trial in 2012, the results of which will be published soon. After publication, it is anticipated that the laser treatment will become the new standard of care at the University of Chicago Medical Center to treat early prostate cancer.

**More Sirolimus success in 2015**

One of Cures’ favorite success stories is the amazing tale of Sirolimus as a “miracle cure” for the pediatric blood disorder Autoimmune Lymphoproliferative Syndrome, known as ALPS. Sirolimus, a transplant anti-rejection drug, reverses the deadly symptoms of ALPS in kids with advanced disease that is unresponsive to all other therapies. As a follow-on to our ALPS success, we supported Dr. David Teachey at the Children’s Hospital of Philadelphia to test this drug as a treatment for 6 rare pediatric autoimmune diseases that share characteristics in common with ALPS, including Evans Syndrome, pediatric lupus, and autoimmune hemolytic anemia. In this new trial 85% of patients had a positive response to sirolimus! As soon as the clinical trial ends and the results are published, this repurposed therapy will be immediately usable by clinicians and patients with these conditions throughout the world.
**PoNS on its way to market**

Many years ago Cures took a risk and funded a small clinical trial at University of Wisconsin to test a neuro-stimulation device, called the PoNS, in conjunction with physical therapy as a treatment for multiple sclerosis. Years later, this therapy has been improved and tested in large trials for MS and traumatic brain injury, with potential for many other uses, including stroke and Parkinson’s Disease. 2015 was a milestone year for this therapy, when a company was launched to improve and commercialize this non-invasive device. We are pleased to support and watch Helius Medical take this project forward and can’t wait to see what the future holds for PoNS therapy, which Cures Within Reach helped launch on its current path.

**Repurposing Opportunities for Myelodysplastic Syndrome from Genomic Screening**

Cures Within Reach has supported myelodysplastic syndrome (MDS) researchers at Columbia University in NYC who are doing genetic evaluation of patient samples. The researchers recently discovered a series of mutated genes that seem to be more prevalent in certain MDS patients than in the general population. Several of these genes are known to be regulated by drugs that are already approved for human use. The research team, after getting informed consent from patients, began to test several of these repurposed drugs on patients with these specific gene defects, including the drug all trans-retinoic acid (ATRA). Over half of the patients have responded!

---

**Pet Care Helps Improve Type 1 Diabetes Management**

The University of Texas Southwestern Medical Center, with a grant from Cures Within Reach, conducted a clinical trial that found that incorporating routine pet care into a child’s diabetes self-care plan can significantly improve monitoring of the disease, resulting in lower blood glucose levels.

The test participants in the clinical trial were either provided with a fish, care instructions and recommendations to set up the fish bowl in their bedroom. The control group got a framed photo of a fish. After three months, the test group’s A1C levels (a marker for diabetic control) decreased, while the control group A1C levels increased. Lower A1C levels lead to lower emergency room visits and more stable disease. A $10.00 fish can save thousands of dollars of medical care and can improve patient quality of life!
Researching New Technologies for Storing Encapsulated Insulin Producing Stem Cells

Normally, type 1 diabetes transplant patients are treated with immunosuppressive drugs so that they don’t “reject” the transplant. Unfortunately, those drugs predispose the recipient to dangerous infections and also increase the risk of cancer. A team of scientists at the Sanford Burnham Prebys Medical Discovery Institute, led by Pamela Itkin-Ansari, has studied the effectiveness of a repurposed device, which can encapsulate insulin producing stem cells (not necessarily embryonic stem cells), therefore “hiding” them from the immune system. The pre-clinical studies have demonstrated this approach successful on animals and the treatment is now in a phase I clinical trial.

In early 2015, Pamela Itkin-Ansari received a $25,000 grant from Cures Within Reach to research new technologies to enable preservation of the encapsulated cells. Having the ability to store the repurposed devices preloaded with cells will greatly impact quality control, cost and patient access. Findings have shown that traditional freezing is not effective so Pamela and her team have built new technology for a novel preservation method. Pamela is seeking additional funding for this research as well as another study related to the pathogenesis of Pancreatic Ductal Adenocarcinoma (PDA). Proposals for both of these studies can be found of CureAccelerator.

Earlier Diagnosis for Melanoma

Several years ago a Cures Within Reach Board member recommended a research project at Northwestern University repurposing and updating some diagnostic tools to help general practitioner physicians make better an earlier diagnoses of melanoma. Melanoma is a deadly cancer, but is much more curable if it is caught early. Dr. June Robinson at Northwestern updated these training tools using smartphones and photos as a training device. After two years of Cures’ support, Dr. Robinson was able to secure a federal grant to expand her work that could improve the prognosis for the almost 140,000 patients who will develop melanoma yearly.

The Cluster Headache Support Group Receives Patient Data for Treatment Options

The Cluster Headache Support Group, Inc. (CHSG.org) is a nonprofit, patient-centered organization seeking more effective treatment options for migraine and cluster headache sufferers. Cluster headache is a rare and debilitating neurological disorder that currently has no effective treatment.
The organization currently has two projects on CureAccelerator that are both yielding great because of the platforms data collection capabilities and the direct access to researchers, developers and healthcare stakeholders it provides. The first project, which received two inquiries from researchers within the first day, is looking at ketamine as a treatment for cluster headaches. The second project is exploring cluster headache triggers through three specific TRP sensory channels. CHSG believes that CureAccelerator has the potential for fast turnaround of new studies and ultimately new treatments.

<table>
<thead>
<tr>
<th>Start Date</th>
<th>Partner</th>
<th>Researcher/Project</th>
<th>CWR Funding Amount</th>
<th>Total Budget</th>
<th>Type of Project</th>
</tr>
</thead>
<tbody>
<tr>
<td>11/1/10</td>
<td>Weill Cornell</td>
<td>Dr. Ron Crystal, Gene Therapy Parallel Protocol Repurposing Gene Therapy for Batten Disease</td>
<td>$770,000</td>
<td>$900,000</td>
<td>Clinical</td>
</tr>
<tr>
<td>1/1/11</td>
<td>Massachusetts General</td>
<td>Dr. Denise Faustman, Repurposing BCG for Type 1 Diabetes</td>
<td>$60,000</td>
<td>$120,000</td>
<td>Clinical</td>
</tr>
<tr>
<td>9/1/11</td>
<td>Children's Hospital of Philadelphia</td>
<td>Dr. David Teachey, Repurposing Rapamycin for 7 Autoimmune Childhood Diseases</td>
<td>$54,000</td>
<td>$62,000</td>
<td>Clinical</td>
</tr>
<tr>
<td>8/1/12</td>
<td>Columbia</td>
<td>Dr. Azra Raza, Whole Exome Evaluation to Discover Repurposing Opportunities for MDS_RARS</td>
<td>$1,000,000</td>
<td>$1,200,000</td>
<td>Both</td>
</tr>
<tr>
<td>12/31/12</td>
<td>Seattle Children's Hospital</td>
<td>Dr. Sarah Leary, Repurposing Drugs for Recurrent Pediatric Brain Tumors</td>
<td>$57,000</td>
<td>$76,000</td>
<td>Clinical</td>
</tr>
<tr>
<td>8/15/13</td>
<td>Rush University</td>
<td>Dr. James Young, Repurposing PoNS for MS</td>
<td>$12,500</td>
<td>$45,000</td>
<td>Clinical</td>
</tr>
<tr>
<td>9/9/13</td>
<td>LAT Pharmaceutical</td>
<td>LAT Pharmaceuticals, Repurposing Terlipressin for Ascites</td>
<td>$10,000</td>
<td>$120,000</td>
<td>Preclinical</td>
</tr>
<tr>
<td>10/12/13</td>
<td>Northwestern Memorial</td>
<td>Dr. June Robinson, Creating Teaching Models of Melanoma to</td>
<td>$20,000</td>
<td>$20,000</td>
<td>Preclinical</td>
</tr>
<tr>
<td>Date</td>
<td>Hospital or Center</td>
<td>Researcher/Institution</td>
<td>Project Title</td>
<td>Funding</td>
<td>Start</td>
</tr>
<tr>
<td>----------</td>
<td>--------------------</td>
<td>------------------------</td>
<td>-------------------------------------------------------------------------------</td>
<td>---------</td>
<td>-------</td>
</tr>
<tr>
<td>12/15/13</td>
<td>Nationwide Children's</td>
<td>Dr. Sarah Keim</td>
<td>Testing Repurposing of Available Fatty Acids for Autism</td>
<td>$35,000</td>
<td></td>
</tr>
<tr>
<td>12/15/13</td>
<td>Cincinnati</td>
<td>Dr. Logan Wink</td>
<td>Repurposing Ketamine for Autism</td>
<td>$15,000</td>
<td></td>
</tr>
<tr>
<td>7/31/14</td>
<td>ADF</td>
<td>Dr. Krista Lanctôt</td>
<td>Repurposing Nabilone (Cesamet®) for Alzheimer’s Patients with Agitation</td>
<td>$30,000</td>
<td></td>
</tr>
<tr>
<td>TBD</td>
<td>UCSD</td>
<td>Dr. Pamela Itkin-Ansari</td>
<td>&quot;Stabilizing Insulin Producing Cells in a Repurposed Encapsulation to Produce an Implantable Artificial Pancreas.&quot;</td>
<td>$25,000</td>
<td></td>
</tr>
<tr>
<td>TBD</td>
<td>Nationwide Children's</td>
<td>Dr. Sarah Keim</td>
<td>Fatty Acids for Symptoms of Prematurity</td>
<td>$35,000</td>
<td></td>
</tr>
<tr>
<td>TBD</td>
<td>Weill Cornell MC</td>
<td>Dr. Chani Traube</td>
<td>Quetiapine as Treatment for Pediatric Delirium</td>
<td>$25,000</td>
<td></td>
</tr>
<tr>
<td>TBD</td>
<td>Rush Medical Center</td>
<td>Dr. Jeff Borgia</td>
<td>Biomarkers for Differentiating Malignant from Benign Lesions in High-Risk Patients Who Underwent Spiral CT Scans.</td>
<td>$30,000</td>
<td></td>
</tr>
<tr>
<td>5/25/15</td>
<td>Epsilon 3</td>
<td>Karl Altenhuber</td>
<td>“HIF-1 signaling interference in polycystic kidney disease”</td>
<td>$10,000</td>
<td></td>
</tr>
<tr>
<td>TBD</td>
<td>Ulm University Hospital</td>
<td>Prof. Dr. Marc-Eric Halatsch</td>
<td>&quot;A proof of concept clinical trial assessing the safety of the coordinated undermining of survival paths by 9 repurposed drugs combined with metronomic temozolomide (CUSP9v3 Treatment Protocol) for recurrent glioblastoma&quot;</td>
<td>$10,000</td>
<td></td>
</tr>
</tbody>
</table>
## The Launch of CureAccelerator™

In May, Cures Within Reach received a grant from the Robert Wood Johnson Foundation in 2014 to build The Cure Accelerator, the world’s first online, interactive platform dedicated to repurposing research, launching publicly in June, 2015. CureAccelerator drives the pace of repurposing research by connecting researchers, funders, clinicians, the biomedical industry and patient groups to deliver more treatments to more patients more quickly.

<table>
<thead>
<tr>
<th>Date</th>
<th>Institution</th>
<th>Project Description</th>
<th>Initial Grant</th>
<th>Total Grant</th>
<th>Type</th>
</tr>
</thead>
<tbody>
<tr>
<td>10/1/15</td>
<td>Johns Hopkins University School of Medicine</td>
<td>Dr. Gregory Riggins, A Phase I Trial for Recurrent Pediatric Brain Cancers using Mebendazole Diseases/Conditions: Medulloblastoma, Glioblastoma</td>
<td>$7,600</td>
<td>$76,000</td>
<td>Clinical</td>
</tr>
<tr>
<td>10/1/15</td>
<td>Johns Hopkins University School of Medicine</td>
<td>Dr. Gregory Riggins, Compassionate Use Delivery of Mebendazole for Pediatric Medulloblastoma, Glioblastoma</td>
<td>$3,400</td>
<td>$4,500</td>
<td>Clinical</td>
</tr>
<tr>
<td>10/1/15</td>
<td>Rush University</td>
<td>Dr. James Young, Repurposing PoNS for Parkinson’s Disease</td>
<td>$45,500</td>
<td>$60,000</td>
<td>Clinical</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Current Total</td>
<td>$2,339,000</td>
<td>$3,519,500</td>
<td></td>
</tr>
</tbody>
</table>
A public launch of CureAccelerator took place in Chicago on May 27 as part of the Cures Within Reach BioScience Awards of the Midwest, sponsored by Astellas, Takeda Pharmaceutical and PwC. Industry leaders from across the globe expressed their enthusiasm at this event for this revolutionary platform. The launch event was chaired by James Robinson, President of Astellas Pharma US, and Dr. Chirinjeev Kathuria, Chairman of New Generation Power.

“Repositioning existing drugs for new diseases represents the most cost and time effective means to systematically deliver new treatments to patients in need. However, the business case for any single stakeholder remains challenging. CureAccelerator provides the essential coordination function, and ensures the unified focus to translate new drug-disease hypotheses, through clinical testing to patient care,” adds Craig Webb, Chief Scientific Officer, NuMedii, Inc.

Since its launch, CureAccelerator has secured 300 users and created nine funding research partnerships in diseases such as pediatric delirium, pediatric cancer, lung cancer, premature births, polycystic kidney disease and Parkinson’s disease. All of our programs moving forward will be connected to this tool.

Our goal is to grow the number of users to 1,000 by January 2016; have a Version 2.0 in place early in 2016; release a Version 3.0 in 2016 (with privacy controls for industry); and have 20 projects funded through the portal in 2016.

“CureAccelerator is a great opportunity to improve patients’ lives. I know that when I connect with like-minded people, together we can accelerate and enhance the impact of repurposing research.” Gauthier Bouche, Medical Director, AntiCancer Fund
Looking Beyond the Horizon

Our programs are growing, and we look forward to sharing new initiatives with you in the coming years. Here are headlines to look for in 2016 and beyond:

- CureAccelerator reaches its goal of 100 projects in 100 days, grows to 1,000 users and becomes the go-to place for repurposing research
- Cures Within Reach lead in the exploration of generic drugs as a resource for new treatments and reduced cost of care
- A social finance pilot program announced in the UK, testing generics for rare disease
- Cures Within Reach and the Canadian Institutes of Health Research work together to fund collaborative research repurposing drugs for rare disease.
- Cures Within Reach launches a repurposing social enterprise to develop a mission-aligned revenue stream: the LoPro Pharmaceutical Company

Fiscal Year 2014-15 Financial Summary

<table>
<thead>
<tr>
<th>Contributions/Interest</th>
<th>$1,074,697</th>
</tr>
</thead>
<tbody>
<tr>
<td>Expenses</td>
<td></td>
</tr>
<tr>
<td>Programs</td>
<td>$811,775</td>
</tr>
<tr>
<td>General</td>
<td>$183,816</td>
</tr>
<tr>
<td>Total</td>
<td>$995,591</td>
</tr>
<tr>
<td>Net Assets</td>
<td>$1,220,185</td>
</tr>
<tr>
<td>Research commitments</td>
<td>$415,856</td>
</tr>
</tbody>
</table>
Our Staff and Volunteer Leadership Team

Dr. Bruce Bloom, President and Chief Science Officer of Cures Within Reach

His journey to this position started in February 2002, when he became the Executive Director of Goldman Philanthropic Partnerships, a 501(c)(3) private operating foundation. In 2005, when Goldman Partnerships created the public charity Partnership for Cures to carry on the Goldman mission, Dr. Bloom became President and Chief Science Officer. In October 2012, Partnership for Cures changed its name to Cures Within Reach to better reflect the focus of its mission: repurposing drugs and other treatments to drive more treatments to more patients more quickly.

Dr. Bloom was profiled in the Chicago Sun Times by financial columnist Theo Pincus and by author Lenore Skenazy was quoted several times in Newsweek in June 2009 and in May 2010. He and Cures Within Reach have been featured in Chemical Engineering News, Fierce Biotech, How to Get to Next, Discover Magazine, the Marquette Intellectual Property Review and the European Pharmaceutical Review.

Dr. Bloom was elected an International Ashoka Fellow in 2009. Ashoka: Innovators for the Public recognizes social entrepreneurs for their system-changing solutions to the world's most urgent social problems. In 2013, Dr. Bloom was selected as a “Alumni of Distinction” at the 125th Anniversary Celebration of IIT Chicago-Kent College of Law. His business experience spans not-for-profit and for-profit work in medical research, law, healthcare, medical malpractice insurance, risk management, regulatory affairs, product development, food service, art, and education.

Dr. Bloom holds a Juris Doctor degree from the IIT Chicago-Kent College of Law, a Doctor of Dental Surgery degree from University of Illinois Medical Center, and a Bachelor of Science degree in Biology from University of Illinois. He is an adjunct faculty member at Kendall College, has been a lecturer at the University of Illinois Chicago for 15 years, and was a senior lecturer at Northwestern University for 6 years. Dr. Bloom has taught Business Law and Risk Management to thousands of health care and other professionals since 1985.

Dr. Bloom currently serves as an editor to the Journal of Drug Repositioning, Rescue and Reuse, is the founding Secretary of the International Drug Repurposing Society, a Trustee of the Kendall College
Charitable Trust, a Board member of the Judy Hirsch Foundation, a Science Advisor to the Marian Falk Trust, a member of the Science Advisory Board of Rediscovery Life Sciences, SAB member for the GARROD AKU Consortium, member of the Board of Councilors of Midwestern University, and a Client Advisor to the Northwestern Mutual Financial Network.

He recently completed terms as Chairman of the Board of Pathways to a Better World, President of the Charles E. Culpeper Science Advisory Boards, a Medical Research Advisor to the LUNGevity Foundation, a Policy Advisor to AccelerateProgress.org, a Science Reviewer for the ACS Lung Cancer Grant Program and the CHEST Foundation Grant Program, Vice-Chair of the Kendall College School of Business Advisory Board, and Trustee of the Menninger Clinic Foundation. Dr. Bloom is a host of the Clinician's Roundtable heard on ReachMD.com and on XM 160, and a facilitator for Pathways to Successful Living.

Amy Conn, Director of Advancement

Amy leads communications, development and operations for Cures Within Reach. Her work spans grant-writing, donor relations, sponsorship development, board development, marketing and event support. She is happy to be a part of the important work of Cures Within Reach and to participate in driving patient-focused research.

Her first career has been as a classical musician, performing and teaching extensively. She describes her work as a soloist with orchestras and chamber groups across the country as "high pressure project management."

Amy received her Bachelor of Music degree from Northwestern University, Pi Kappa Lambda. She was a sought-after voice teacher in the Chicago area, holding adjunct faculty positions at the Chicago Academy for the Arts and DePaul University, receiving the "Young Leader's Award" from the National Association of Teachers of Singing and serving as Vice President of their Chicago Chapter. While continuing to perform selectively, Ms. Conn recently completed a certificate through the University of Chicago's Graham School of Continuing Education entitled Leadership in Sustainability Management.
Kristin Deuber, Director of Marketing

Kristin brings 17 years of marketing and public relations experience to Cures Within Reach. During her career, she has developed, managed and implemented marketing programs for clients ranging from non-profit organizations to Fortune 500 companies, with a deep expertise in the healthcare industry. Kristin holds an MBA degree from Franklin University and a Bachelor of Arts in Journalism degree from The Ohio State University. She has also been an adjunct marketing and public relations professor at The Ohio State University, Ohio Dominican University and Franklin University. Kristin is an accredited member of the Public Relations Society of America (PRSA), Past-President of the Central Ohio PRSA Chapter and former board member of the Healthcare Business Women’s Association.

Susan Braze, Administrative Coordinator

Susan joined the Cures Within Reach team in May 2014. Susan graduated from Columbia College Chicago in 2008 with a B.A. in Theatre. Since graduating she’s performed sketch and improve at Gorilla Tango Theatre and Donny’s Skybox at The Second City. She’s been a shift supervisor at The Coffee & Tea Exchange in the Lakeview neighborhood of Chicago since 2007 and can foam a cappuccino like nobody's business. Susan has a passion for health & wellness, bargain shopping, avocados, and animal welfare. She is a proud vegan and dedicated runner.

Boards and Committees

**Executive Board**
Elizabeth Downey, Chair
Margaret Christie, Secretary
Golan and Christie
Steve Braun, Treasurer
Northwestern Mutual
Solveig Direnzo
Hospira Corporation
Lucy Mancini-Newell

Kiran Consulting
Lorri Provow
Pfizer, Inc.-Retired

**Business Advisory Board**
Timothy P. Walbert
Horizon Pharma plc, Chair

Don Frail
Allergan

**Conceptual MindWorks/HHS**

Dean L. Kamen
DEKA R&D

Ben Katz
HSBC

Dr. Norbert Riedel
Naurex, Inc

Brian Roden
Greenfield Chemicals
Michael S. Rosen
Rosen BioScience Strategies

Nancy S. Searle
Civic Consulting Alliance

Nancy Sullivan
Illinois VENTURES

Jeff Trotter
Continuum Clinical

James L. Tyree
Retired, Abbott

Science Advisory Board
Russell Altman
Stanford University

Luis Caveda
Caveda Consulting

Kevin Clark
VA Greater Los Angeles

Tim Cunniff
Marathon Pharmaceuticals

Nihar R. Desai
Yale School of Medicine

Stephen Kron
University of Chicago

Mitchell Seymour
University of Michigan

Jeffrey Sherman
Horizon Pharma plc

Young Professionals Board
Alexandria Bobe, Chair
University of Chicago

Lisa Jaimovich, Vice-Chair
Marsh & McLennan

Tyler Wanke,
Fundraising Chair
Innoblative

Charlotte Dretler,
Media/Communications Chair
Edelman

Julia Egofske, Events Chair
Horizon Pharma plc

Katie Igartua, Treasurer
University of Chicago

Susan Braze, Secretary
Cures Within Reach

Cassandra Direnzo
See3 Communications

Matthew Frazee
CBRE

Jonathan Gunn
Briteseed

Daniel Leventhal
University of Chicago

Daina Ringus
University of Chicago

CureAccelerator Advisors
Pat Fuller
Technology Management Group

Josh Naylor
University of Illinois at Chicago

Development Team
Desiree Quizon-Colquitt
BioVectra Inc., Chair

Lee DeWitt
Biddle Sawyer Corporation

Joel Dysart
Retired

Nicolas Gerst
Doug Johnson
PrimeGuard Medical

Peter Kuperberg
Gofen and Glossberg

Colin Marr
BioVectra

Robert Miller
Millco Investments

Bhavani Moodabagil
Strategic Marketing Insights

Hope Mueller
Crealta Pharmaceuticals

Sanford Prizant
The Prizant Group

Nancy Reid
Consolidated Printing Company
2015 Donors

$10,001+
Apollo Education Group
Astellas Pharma US
Auctions by Cellular
Edmond and Alice Opler Foundation
Forest City Science+Technology
Frank Hirsch
Golan & Christie
Goldman Philanthropic Partnerships
K&L Gates
Mightybytes
Northwestern Mutual Foundation
PwC
Rachel & David Grund
Robert Wood Johnson Foundation
Takeda Pharmaceuticals
The Kahlert Foundation

$5001-10,000
Anonymous
Celgene Global Health
Downers Grove Professional Firefighters Association
Joel and Mari Dysart
Margaret Christie
Mike Keslar
Morgan Family Foundation
Richard Silverman
Robert Miller

$1001-5000
Accenture
Andrew Gabelman
Anonymous
Arturo Saenz
Assembly BioSciences
Beau James
Beecken Petty O'Keefe & Company
Berger Excavating Contractors
Bill Brennan
BioMarin Pharmaceutical Inc.
Bob Jensen
Butler Rubin Saltarelli & Boyd LLP
Calibrium
Carl Ruzicka
CBRE
Celebrate Life Foundation
Charles Barancik
Crealta Pharmaceuticals
Daniel DeCore
Donise Gehrisch
Duchossois Family Foundation
Eli Lilly
Elizabeth S. Downey
Elizabeth Walder
First Bank of Highland Park Foundation
Foundation For Advancing Technology
Gillian Stoettner
Glass Solutions
Greenfield Chemical
Health Care Service Corporation
Hope Mueller
Horizon Pharma plc
IDT
Jim Vandenbergh
Joel Dysart
Julien Bloom Trust
Larry Foy
Manoj Mahenthiran
Marathon Pharma
Marc Pozan
Margaret Christie
Mark & Mary Ann Kaufman Family Fund
Marsh & McLennan
Medical Center of the Americas Foundation
Mesirow Financial
Milco Investments
Naurex, Inc.
Old World Industries
Pat and Cherie Nichols
PhRMA
Pinnacle Biologics
Qualcomm Matching Grant Program
Richard Rice
Robert Melsher
Robert Stuchiner
Sarah Bader
Stephen and Lois Eisen
Stephen Kron
The Hill Group
The McTigue Financial Group
Thomas Chustak
Wickstrom Auto Group
Wintrust

$250-1000
ABN AMRO
Ada Tikkanen
Al Capitanini
Alan Arnold
Alan Siegal
Alexandra Hendrickson
Alice Palella
Allen Webb
Amy and Chris Sakalosky
<table>
<thead>
<tr>
<th>Company/Name</th>
<th>Name</th>
<th>Company/Name</th>
<th>Name</th>
</tr>
</thead>
<tbody>
<tr>
<td>Poblocki Sign Company</td>
<td>Scott Friedman</td>
<td>The Ken Holland Memorial Fund</td>
<td>Thomas and Darlene Furst</td>
</tr>
<tr>
<td>Ralph Caruso</td>
<td>Sean McNally</td>
<td>Thomas Brent</td>
<td>Thomas Brent</td>
</tr>
<tr>
<td>RCM Laboratories</td>
<td>Shelly Rosen</td>
<td>Thomas C. &amp; Darlene J. Furst</td>
<td>Thomas V. Hogan</td>
</tr>
<tr>
<td>Richard DiMarchi</td>
<td>Solveig Direnzo</td>
<td>Thomas Washburn</td>
<td>Timothy Shanahan</td>
</tr>
<tr>
<td>Robert Hicks</td>
<td>Stephen King</td>
<td>Trucia Drummond</td>
<td>Tyler Wanke</td>
</tr>
<tr>
<td>Robert Melsher</td>
<td>Steve Braun</td>
<td>Wilken Benjamin II</td>
<td></td>
</tr>
<tr>
<td>Robert Tominson</td>
<td>Steve Cantor</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Rodger Davis</td>
<td>Steve Goldsher</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Roger Lumpp</td>
<td>Susan Fried</td>
<td></td>
<td></td>
</tr>
<tr>
<td>S. James Perlow</td>
<td>Synergy Construction Group, Inc.</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Sagitta Therapeutics</td>
<td>Ted &amp; Becky Catino</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**Stay In Touch**

[www.cureswithinreach.org](http://www.cureswithinreach.org)

[http://CureAccelerator.org](http://www.cureswithinreach.org)

Cures Within Reach
Illinois Science + Technology Park
8025 Lamon Ave., Suite 440
Skokie, IL 60077
(847) 745-1246
[info@cureswithinreach.org](mailto:info@cureswithinreach.org)

Twitter: CuresWReach
Facebook: P4Cures
LinkedIn : Cures Within Reach